Australia markets closed

Zymeworks Inc. (ZYME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.52+0.22 (+2.14%)
At close: 04:00PM EDT
10.52 0.00 (0.00%)
After hours: 04:11PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.30
Open10.35
Bid10.50 x 300
Ask10.54 x 100
Day's range10.34 - 10.57
52-week range6.01 - 13.14
Volume440,419
Avg. volume572,800
Market cap742.377M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)-1.72
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.63
  • GlobeNewswire

    Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

    VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. “Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and

  • GlobeNewswire

    Zymeworks Announces Participation in Upcoming Investor Conferences

    VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: 23rd Annual Needham Virtual Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present

  • GlobeNewswire

    Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

    Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (US) with anticipated completion of regulatory submission in 1H 2024 by our partner, Jazz PharmaceuticalsInitiation of Phase 3 confirmatory tri